News archive

Adiposity research with cells

Thursday, 06 July 2023 10:25

A team of researchers led by Prof. Dr. Anne Spang from the Biozentrum of the University of Basel has studied the lipid metabolism process in yeast cells and human cells in more detail. They have discovered that the protein Arf1 (ADP-ribosylation factor 1) acts like a molecular switch to regulate how many lipids are converted into ATP in the body.

Scientists at the Wyss Institute at Harvard University in Boston have recreated a model of reflux disease (barrett's disease) in vitro. The goal is to gain a better understanding of the cellular and molecular triggers of this disease and to develop appropriate drug therapies.

This year's World Summit on Microphysiological Systems was held in Berlin from June 26 to 30. 1,297 participants from numerous countries had registered. It was impressive to see how many young scientists dedicated themselves to the development of animal-free methods with the ultimate goal of finding better treatments through human-specific research, reducing the financial burden and time required to do so, and replacing animal experimentation.

Dr. Eckhard von Kreutz, former senior vice president and head of translational sciences at Bayer Pharmaceuticals, recently described on the LinkedIN platform eight steps necessary to completely replace animal testing.

The Jena-based biotechnology company Dynamic42, a spin-off from the Center for Sepsis Control and Care (CSCC) at Jena University Hospital, has reached a milestone. It has secured growth financing from bm-t Beteiligungsmanagement Thüringen GmbH (bm-t) and another financier.

DNTOX GmbH, based in Düsseldorf, Germany, is a bio-analytical testing laboratory that screens chemicals for its potential to disrupt human brain development and cause developmental neurotoxicity (DNT) without using animals. With its service, the research team has convinced investors and can now dispose of 1.4 million euros in start-up funding.

An article from Nature Medicine provides a good insight into the current debate about the recognition of results from animal-free methods in drug development.

A few days ago, the Environmental Protection Act, Bill S-5, was revised in Canada. It includes amendments that require the Canadian government to replace or reduce animal testing for toxicity testing of chemicals where possible and to publish a plan within the next two years to encourage the development and timely incorporation of alternative strategies for toxicity testing.

The Eva Luise and Horst Köhler Foundation, in cooperation with the association ACHSE e. V., has offered a research prize for rare diseases since 2008.

Researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), headed by Prof. Dr. Claus-Michael Lehr, have developed a novel method to specifically place biofilms on lung cells in the laboratory. The model system produced by means of "bioprinting" should help to better understand infection processes and assist in the research of new active substances.